Kedrion Group purchases RhoGAM products from OCD
The Kedrion Group has completed its acquisition of the RhoGAM line of products from Ortho-Clinical Diagnostics (OCD), a Johnson & Johnson company. The acquisition includes the transfer of the Rho(D) Immune Globulin (Human) RhoGAM Ultra-Filtered Plus and Rho(D) Immune Globulin (Human) MICRhoGAM Ultra-Filtered Plus products, as well as Somerset Laboratories, a subsidiary of OCD. The deal will aim to complement Kedrion's portfolio of plasma-derived products, including those for the treatment of the haemolytic disease of the newborn, haemophilia and immune deficiencies.
Developed in the US and manufactured and distributed by OCD, RhoGAM is prescribed Rho(D) immune globulin for the prevention of Rh haemolytic disease of the newborn (HDN). Prior to the development of RhoGAM, it is estimated that more than two dozen babies in the US were lost daily due to the effects of haemolytic disease of the newborn (HDN). Now, HDN has been virtually eliminated in most developed countries, although the risk of anti-D sensitisation is still a problem in several developing countries where prenatal care is suboptimal.